Neurocrine Biosciences, Inc. stays a Buy as Ingrezza, Crenessity, and Vykat drive 44% revenue growth; see valuation, patents ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Neurocrine Biosciences NBIX) has quietly become one of biotech's strongest earnings stories, combining impressive commercial ...

Neurocrine Biosciences earns Bull of the Day on rising earnings forecasts, while Ryanair is Bear of the Day as weaker fares ...

Last year, Neurocrine’s Ingrezza failed a phase 2 trial in pediatric Tourette Syndrome patients, prompting the company to use what it learned in designing a new phase 2b. But now Ingrezza has flunked ...

Neurocrine Biosciences has successfully diversified beyond Ingrezza, with Crenessity's rapid adoption validating its multi-franchise commercial strategy. NBIX's late-stage neuropsychiatry pipeline, ...

SAN DIEGO, Jan. 16, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that a new analysis of INGREZZA ® (valbenazine) capsules, published in the Journal of Affective ...

While 2017 saw the entrance of the first two drugs for tardive dyskinesia, the percentage of TD patients who are actually diagnosed remains in the single digits. Neurocrine is looking to change that ...

Neurocrine Biosciences Inc. (NASDAQ:NBIX) is one of the 11 best debt-free stocks to invest in right now. Following a recent investor meeting with Neurocrine Biosciences’ senior leadership, Guggenheim ...

Lupin has received approval from the FDA for Valbenazine Capsules, 40 mg and 80 mg, which is a generic of Neurocrine Biosciences’ Ingrezza. Lupin is one of the first ANDA applicants and is eligible ...

The performance of the tardive dyskinesia drug Ingrezza had sell-side analysts gushing over Neurocrine Biosciences, Inc. NBIX's third-quarter results. Given the buoyancy surrounding Ingrezza, analysts ...